Elekta signs brachytherapy sales sharing agreement with Xoft
8 February 2008
Oncology systems supplier Elekta has signed an
agreement with California-based Xoft, Inc developer of the Axxent electronic
Under the agreement, Elekta will share identified
sales opportunities for Axxent in the radiation oncology market. This
non-exclusive agreement allows Elekta to expand its revenue to include
procedures performed outside shielded rooms by partially sharing in revenues
Xoft receives from the sale of the electronic brachytherapy controller.
Additionally, the companies will explore other areas of collaboration, which
could include international sales and joint development agreements.
Michael Klein, president and CEO of Xoft said, "This represents a true
win-win situation for both companies. The Axxent system rounds out Elekta's
product offering with an innovative new method of delivering partial breast
irradiation in minimally shielded rooms, giving sites the ability to
maximize availability of their vaults for procedures that can only be
performed in shielded rooms. For Xoft, Elekta's strong radiation oncology
presence and market share offers tremendous visibility and the ability to
dramatically expand access to this important new treatment option.
expansion into new treatment areas, which are pending FDA clearance, will
extend the use of the electronic brachytherapy to endometrial and rectal
indications and therefore allow for broader sales opportunities working with
Joseph K. Jachinowski, President and CEO of Elekta North America
said, "Xoft's electronic brachytherapy system is a good example of
technology improving care through the use of electronic x-ray-based therapy
that can be delivered in a variety of clinical settings. This is a strong
complement to Elekta's suite of oncology products designed to make cancer
care easier for and more accessible to physicians and patients."
Save this page on del.icio.us